Chemical delivery systems and soft drugs: Retrometabolic approaches of drug design

Saudi Pharmaceutical Journal

Volumn 22, Issue 4, 2014, Pages 290-302

  Bhardwaj, Yashumati Ratan ^a   Pareek, Ashutosh ^a   Jain, Vivek ^a   Kishore, Dharma ^a  

^a BANASTHALI UNIVERSITY   (India)

Author keywords

Absorption; Angiotensin converting enzyme; Chemical delivery system; Distribution; Excretion; Metabolism; Retrometabolic drug design; Soft drug design; Soft drugs

Indexed keywords

1 MALONYL 1,4 DIHYDROPYRIDINE; 1,4 DIHYDROPYRIDINE DERIVATIVE; ALKYLATING AGENT; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORAMINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN A DERIVATIVE; DIHYDROPYRIDINE PYRIDINIUM SALT; DRUG CARRIER; DRUG METABOLITE; ESTER DERIVATIVE; GESTAGEN; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE DERIVATIVE; PROGESTERONE; PYRIDINIUM DERIVATIVE; QUATERNARY AMMONIUM DERIVATIVE; TESTOSTERONE; UNCLASSIFIED DRUG;

CHEMICAL DELIVERY SYSTEM; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; HUMAN; NONHUMAN; RETRO METABOLIC DRUG DESIGN; REVIEW; SOFT DRUG DESIGN; STRUCTURE ACTIVITY RELATION; STRUCTURE METABOLISM RELATIONSHIP;

EID: 84906244939     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2013.04.004     Document Type: Review

References (56)

1. Albert A. Chemical aspects of selective toxicity. Nature 1958, 182:421-427.
2. Ariens, E.J., Simonis, A.M., 1977. In: Drug Design and Adverse Reactions, Alfred Benzon Symposium X, Munksgaard, pp. 317-330.
3. Balant L.P., Doelker E. Burger's Medicinal Chemistry and Drug Discovery 1995, 1:949-982. Wiley interscience, New York.
4. Baxter A.J., Carr R.D., Eyley S.C., Fraser-Rae L., Hallam C., Harper S.T., Hurved P.A., King S.J., Meghani P. (R)-2-(3-mercapto-2(S)-methyl-1-oxo-Propoxy)-3-(methylthio) propanoic acid, the first ultra short acting angiotensin converting enzyme inhibitor. J. Med. Chem. 1992, 35:3718-3720.
5. Bodor N. Design of biopharmaceutical properties through prodrugs and analogs 1977, 98-135. Academy of pharmaceutical sciences, Washington DC. E.B. Roche (Ed.).
6. Bodor N. Designing safer drugs based on soft drug approach. Trends Pharmacol. Sci. 1982, 3:53-56.
7. Bodor N. The soft drug approach. Chem. Tech. 1984, 14:28-38.
8. Bodor N. Novel approaches to the design of safer drugs by site specific chemical delivery systems. Adv. Drug Delivery Syst 1985, 111-127. MSR Foundation, Bombay.
9. Bodor N. Targetting of drugs to the brain. Methods Enzymol. 1985, 112:381-396.
10. Bodor N. Redox drug delivery systems for targeting drugs to the brain. Ann. NY Acad. Sci. 1987, 507:289-306.
11. Bodor N. Prokai L.Site and stereo specific ocular drug delivery by sequential enzymatic bioactivation. Pharm. Res. 1990, 7:723-725.
12. Bodor N. Drug targeting and retro metabolic drug design approaches. Adv. Drug Delivery Rev. 1994, 14:157-166.
13. Bodor N. Design of biologically safer chemicals. Chem. Tech. 1995, 25:22-32.
14. Bodor N. Drug targeting and retrometabolic drug design approaches. Adv. Drug Delivery Rev. 1999, 36:229-254.
15. Bodor N., Brewester M.E. Targeted drug delivery 1991, Vol. 100:231-284. Springer-Verlag, Berlin.
16. Bodor N., Buchwald P. Drug targeting via retro metabolic approaches. Pharmacol. Ther. 1997, 76:1-27.
17. Bodor N., Buchwald P. All in the mind. Chem. Br. 1998, 34:36-40.
18. Bodor N., Buchwald P. Soft drug design: general principles and recent applications. Med. Res. Rev. 2000, 20:58-101.
19. Bodor N., Buchwald P. Burger's medicinal chemistry 2003, Vol. 2:553-608. Wiley Interscience, New York.
20. Bodor N., Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005, 7:E820-E833.
21. Bodor N., Elkouss A. Improved delivery through biological memberanes. LVI. Pharmacological evaluation of Alprenoxime-A new potential antiglaucoma agent. Pharm. Res. 1991, 8:1389-1395.
22. Bodor N., Kaminski J.J. Soft drugs. 2. Soft alkylating compounds as potential antitumor agents. J. Med. Chem. 1980, 23:566-569.
23. Bodor N., Kaminski J.J. Prodrugs and site specific chemical delivery systems. Annu. Rep. Med. Chem. 1987, 22:303-313.
24. Bodor N., Sloan K.B. Soft drugs V: thiazolidine-type derivatives of progesterone and testosterone. J. Pharm. Sci. 1982, 71:514-520.
25. Bodor N., Kaminski J.J., Selk S. Soft drugs: labile quaternary ammonium salts as soft antimicrobials. J. Med. Chem. 1980, 23:469-474.
26. Bodor N., Woods R., Raper C., Kearney P., Kaminski J.J. Soft drugs. A new class of anticholinergic agents. J. Med. Chem. 1980, 23:474-480.
27. Bodor N., Farag H.H., Brewster M.E. Site-specific sustained release of drugs to the brain. Science 1981, 214:1370-1372.
28. Bodor N., ElKoussi A., Kano M., Nakamura T. Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents. J. Med. Chem. 1988, 31:100-106.
29. Bodor N., el-Koussi A.A., Kano M., Khalifa M.M. Soft drugs.7. Soft β-blockers for systemic and ophthalmic use. J. Med. Chem. 1988, 31:1651-1656.
30. Bradshaw J. Chronicles of Drug Discovery 1993, 3:45-81. ACS, Washington DC.
31. Brewester E.M., Estes K.S., Bodor N. Improved delivery through biological memberanes. XXIV. Synthesis, in vitro studies, and in vivo characterization of brain- specific and sustained progestin delivery systems. Pharm. Res. 1986, 5:278-285.
32. Brewester E.M., Anderson W.R., Helton D.O., Bodor N., Pop E. Dose dependent brain delivery of Zidovudine through the use of a zidovudine chemical delivery system. Pharm. Res. 1995, 12:796-798.
33. Brouillette G., Kawamura M., Kumar G.N., Bodor N. Design and evaluation of soft analogs of Propantheline. J. Pharm. Sci. 1996, 85:619-623.
34. Buchwald P., Bodor N. Soft quaternary anticholinergics: Comprehensive quantitative structure-activity relationship (QSAR) with a Linerarised Biexponential (LiniBiexp) model. J. Med. Chem. 2006, 49:883-891.
35. Calvani M., Critelli L., Gallo G., Giorgi F., Gramiccioli G., Santaniello M., Scafetta N., Tinti M.O., De Angelis F. l-carnitine esters as soft broad spectrum antimicrobial amphiphiles. J. Med. Chem. 1998, 41:2227-2233.
36. Chen P., Bodor N., Wu W.M., Prokai L. Strategies to target kyotrophin analogs to the brain. J. Med. Chem. 1998, 41:3773-3781.
37. Drews J. Drug discovery: a historical perspective. Science 2000, 287(5640):1960-1964.
38. Erhardt P.W., Woo C.M., Anderson W.G., Gorczynski R.J. Ultra short acting β-adrenergic receptor blocking agents.2. (Aryloxy) propanolamines containing esters on the aryl function. J. Med. Chem. 1982, 25:1408-1412.
39. Feldman P.L., James M.K., Brackeen M.F., Bilotta J.M., Schuster S.V., Lahey A.P., Lutz M.W., Johnson M.R., Leighton H.J. Design, synthesis and pharmacological evaluation of Ultra short to long acting opioid analgesics. J. Med. Chem. 1991, 34:2202-2208.
40. Ganellin C.R. Chronicles of Drug Discovery 1982, 1:1-38. Wiley-Interscience, New York.
41. Gillette J.R. Effects of induction of cytochrome P-450 enzymes on concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds. Drug Metab. Rev. 1979, 10:59-87.
42. Hassan H.A., Abdel-Aziz M., Abuo-Rahma Gamal El-Din A.A, Farag H.H. 1-Malonyl-1, 4-dihydropyridine as a novel carrier for specific delivery of drugs to the brain. Bioorg. Med. Chem. 2009, 17:1681-1692.
43. Hochhaus G., Chen L.S., Ratka A., Druzgala P., Howes J., Bodor N., Derendorf H. Pharmakokinetic characterization and tissue distribution of the new glucocoid soft drug Loteprednol Etabonate in rats and dogs. J. Pharm. Sci. 1992, 81:1210-1215.
44. Hwang S.K., Juhasz A., Yoon S.H., Bodor N. Soft drugs.12. Design, synthesis and evaluation of soft bufuralol analogs. J. Med. Chem. 2000, 43:1525-1532.
45. Jeffrey A.S., Gregory J.P., Richard F.C., Jill R.C., George F.D., Stephen S.G., David K.J., George W.K., Maggie S.M., Jeffrey H.T., Robert P.W., Paul L.F. Identification and structure-activity studies of novel ultrashort-acting benzodiazepine receptor agonists. Bioorg. Med. Chem. Lett. 2002, 12:3215-3218.
46. Kaminski J.J., Bodor N., Higuchi T. N-halo derivatives IV: synthesis of low chlorine potential soft N-chloramine systems. J. Pharm. Sci. 1976, 65:1733-1737.
47. Katalin P.T., Pá Perjé si, Alevtina D.Z, Xiaoxu L, Laszlo P Design, synthesis, and biological evaluation of novel, centrally-acting thyrotropin-releasing hormone analogues. Bioorg. Med. Chem. Lett. 2002, 12:2171-2174.
48. Lazarova S., Chen J.S., Hamann B., Kang J.M., Homuth-Trombino D., Han F., Hoffmann E., McClure C., Eckstein J., Or Y.S. Synthesis and biological evaluation of novel Cyclosporin A analogues: potential soft drugs for the treatment of autoimmune diseases. J. Med. Chem. 2003, 46:674-676.
49. Ĺenar̈ig F., Fabienne G., Martine D., Pierre B., Georges D., Jean C., Ahmed A., Francis M., Louisa Barŕe, Vincent L. Synthesis, radiosynthesis and biological evaluation of 1,4 dihydroquinoline derivatives as new carriers for specific brain delivery. Org. Biomol. Chem. 2009, 7:3666-3673.
50. Little R.J., Bodor N., Loftsson T. Soft drugs based on hydrocortisone: The inactive metabolite approach and its application to steroidal anti-inflammatory agents. Pharm. Res. 1999, 16:961-967.
51. Mannering G.J. Concepts in drug metabolism 1981, 53-166. Marcel Dekker, New York. B. Testa, P. Jenner (Eds.).
52. Picot A., Macherey A.C. The practice of medicinal chemistry 1996, 643-670. Academic press, London. C.G. Wermuth (Ed.).
53. Pop E., Loftsson T., Bodor N. Solublization and stabilization of a benzyl penicillin chemical delivery system by 2-hydroxylpropyl-β-cyclodextrin. Pharm. Res. 1991, 8:1044-1049.
54. Prokai T.K., Prokai L., Bodor N. Brain targeted delivery of a leucine-enkaphalin analog by retrometabolic design. J. Med. Chem. 1996, 39:4775-4782.
55. Stella V.J. Prodrugs as novel drug delivery systems 1975, 11-15. ACS, Washington DC. T. Higuchi, V.J. Stella (Eds.).
56. Stout D.M., Black L.A., Barcelon-Yang C., Matier W.L., Brown B.S., Quon C.Y., Stampfli H.F. Esters derivatives of 2,6-bis (1-pyrrolidinylmethyl)-4-benzamidophenol as short acting antiarrythmic agents.1. J. Med. Chem. 1989, 32:1910-1913.